SightLine raises $107M fund for med tech investments

Minnesota's SightLine Partners has $107 million and an eye out for promising late-stage medical technology companies. SightLine plans to use its oversubscribed second fund to provide creative financing options for device and diagnostics outfits working to get novel technologies to market. More

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.